Which company develops and manufactures Acalabrutinib?

Acalabrutinib/Acalabrutinib is developed and produced by AstraZeneca Pharmaceuticals in the United States. Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.

Acalabrutonis a Brutontyrosine kinase inhibitor that prevents B cell proliferation, trafficking, chemotaxis, and adhesion. It is taken every 12 hours and may cause other effects such as atrial fibrillation, other malignancies, cytopenias, bleeding and infection. Acalabrutinib is a small molecule inhibitor of BTK. Acalabrutinib and its active metabolite ACP-5862 are similar to The cysteine residue (Cys481) in the active site of BTK forms a covalent bond, thereby inhibiting the BTK enzyme activity. Therefore, acalatinibinhibits BTK-mediated activation of downstream signaling proteins CD86 and CD69, ultimately inhibiting malignant B cell proliferation and survival. Although ibrutinib is generally considered a first-in-class BTKinhibitor, acalabrutinibis considered a second-generation BTKinhibitor primarily due to its greater selectivity and inhibition of BTK's targeting activity, as well as its higher IC50or ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK There was little inhibition of the kinase activity of , LCK, LYN, SRC, and YES1. In fact,Acalabrutinib is rationally designed to be more potent and selective than ibrutinib, while theoretically exhibiting fewer side effects because the drug's off-target effects are minimized. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0